C
Cajal Neuroscience
A drug discovery company focused on neurodegenerative disease
About Cajal Neuroscience
Cajal Neuro is a cutting-edge biotech startup that operates in the neuroscience field. The company is named after Santiago Ramón y Cajal, a Spanish scientist who laid the groundwork for modern neuroscience. Cajal Neuro is dedicated to developing new drug targets and therapeutics for neurodegenerative diseases, a market that is in desperate need of innovative solutions.
The company uses a combination of high-throughput microscopy, functional genomics, and multi-omics analyses to achieve its goals. In simpler terms, they use advanced imaging techniques to study cells in large volumes, apply genetics to understand the function of genes in the nervous system, and use multi-omics analyses to study biological systems as a whole. This integrated approach allows them to identify potential drug targets and develop new treatments for diseases such as Alzheimer's and Parkinson's.
Cajal Neuro's business model revolves around the research and development of these new treatments. They likely generate revenue through partnerships with larger pharmaceutical companies, licensing agreements, and potentially government grants for their research. Their clients would primarily be other businesses in the pharmaceutical industry, as well as healthcare providers and patients suffering from neurodegenerative diseases.
In summary, Cajal Neuro is a promising startup in the neuroscience field, using advanced techniques to develop new treatments for neurodegenerative diseases. Their work could potentially revolutionize the treatment of these diseases, providing hope for millions of patients worldwide.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2022 | $96M | $384M | Two Sigma Ventures · Dolby Family Ventures · Evotec · Lux Capital | ↗ |
| SPINOUTOther financing | Jan 2020 | $0 | — | Columbia University · Cold Spring Harbor Laboratory · Baylor College of Medicine | — |
Growth signals
Latest recorded traffic for Cajal Neuroscience is 2.6K monthly website visits, up 52.9% over the last three months. Cajal Neuroscience's team grew 5.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cajal Neuroscience in the Seattle ecosystem
The Cajal Neuroscience office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A6 investors entered at this stage
Two Sigma Ventures
Dolby Family Ventures
Evotec
The Column Group
Bristol-Myers Squibb
Alexandria Venture Investments
Other known investors3 additional known investors
Baylor College of Medicine
Cold Spring Harbor Laboratory
Columbia University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cajal Neuroscience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cajal Neuroscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









